Compare Abbott Laboratories (ABT) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs ProShares UltraPro S&P500 — how do they compare? Abbott Laboratories trades at $95.23 (market cap $166.94B), while ProShares UltraPro S&P500 trades at $140.17. The key difference: Abbott Laboratories pays a 2.63% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | UPRO | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $150.93 |
52-Week Low | $82.57 | $89.29 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
UPRO, the ProShares UltraPro S&P 500 ETF, trades at $144.41, up 2.64% with a bullish technical outlook from moving averages. The leveraged ETF faces neutral sentiment from oscillators while tracking S&P 500 performance. Recent news highlights sector rotation from tech stocks and mixed analyst views on S&P 500 targets ranging from 8,000 to 8,800 by year-end 2026.
The leveraged structure amplifies both gains and losses, making UPRO suitable for short-term trading amid expected S&P 500 volatility. Key risks include Fed policy uncertainty and sector rotation pressures, while opportunities exist if the S&P 500 reaches analyst targets. Earnings season performance and AI sector momentum remain critical catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
